Hydroxychloroquine (Indication Antiphospholipid Syndrom)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Ye, 2017 Elsenity, 2022 20.39[0.03; 4.81]1149not evaluable Growth parameters and prematurity Small for gestational age (weight) Sciascia, 2016 Ye, 2017 Gerde, 2021 30.42[0.18; 0.99]33216not evaluable Preterm (< 37 weeks) Sciascia, 2016 Ye, 2017 20.45[0.09; 2.11]56146not evaluable Low birth weight (< 2500g) Ye, 2017 10.42[0.22; 0.83]47112not evaluable Very preterm (28 to 32 weeks) Mekinian, 2015 10.68[0.15; 3.01]835not evaluable Maternal consequences Preeclampsia Sciascia, 2016 Ye, 2017 Latino, 2020 Gerde, 2021 40.32[0.14; 0.70]46241not evaluable Caesarean Sciascia, 2016 Elsenity, 2022 20.50[0.29; 0.86]6682not evaluable Abruptio placentae (retroplacental hematoma) Sciascia, 2016 10.24[0.01; 4.81]334not evaluable Gestational diabetes Ye, 2017 10.98[0.46; 2.09]30126not evaluable Maternal consequences (as a whole) Ruffatti, 2018 10.32[0.14; 0.72]3594not evaluable Neonatal disorders Low Apgar score (< 7) (at 5 min) Elsenity, 2022 10.38[0.19; 0.75]2233not evaluable Neonatal death (< 28 days of life) Elsenity, 2022 10.50[0.12; 2.05]733not evaluable Neonatal disorders (as a whole) Mekinian, 2015 10.44[0.07; 2.88]535not evaluable Neonatal infections Elsenity, 2022 10.40[0.11; 1.48]833not evaluable Neonatal medical care Elsenity, 2022 10.31[0.03; 3.04]1133not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Mekinian, 2015 Mekinian, 2016 Sciascia, 2016 Ye, 2017 Ruffatti, 2018 Gerde, 2021 Elsenity, 2022 70.37[0.21; 0.65]493437not evaluable Early intrauterine death (< 22 weeks) Sciascia, 2016 Ye, 2017 Gerde, 2021 30.29[0.09; 0.95]110246not evaluable Late intrauterine deaths (> 22 weeks) Ye, 2017 11.12[0.27; 4.59]8126not evaluable0.05.01.0